Laboratory Products

  • New Platform Speeds Development of Cell and Gene Therapies
    Operator manufacturing viral vector in a cGMP environment. Merck’s new VirusExpress™ Platform increases dose yields and reduces process development time for cell and gene therapies.

New Platform Speeds Development of Cell and Gene Therapies

Oct 13 2020 Read 255 Times

Merck has bolstered its viral vector manufacturing capabilities with the launch of its VirusExpress™ Lentiviral Production Platform. This new platform helps to overcome lentiviral production challenges and can reduce process development time by approximately 40%, based on Merck’s experience as a contract development and manufacturing organisation. 

 

“Cell and gene therapies offer the potential for curative treatments and are being developed and commercialised in half the time it has taken traditional therapies,” said Angela Myers, head of Gene Editing & Novel Modalities, Life Science, at Merck. “We are committed to accelerating manufacturing of cell and gene therapies with the ultimate goal of getting these lifesaving treatments to patients faster. By increasing dose yields and dramatically reducing process development time, this new platform will help us reach this goal.”

 

Using a suspension cell line rather than an adherent-based production, coupled with a chemically defined cell culture media and process with built-in scalability, Merck’s VirusExpress™ Platform meets multiple market needs. In addition to accelerating process development, the suspension culture format allows each batch of virus to be larger yielding more patient doses. Additionally, suspension culture is amenable to true scale-up, while being less labour-intensive. The chemically defined medium eliminates the safety, regulatory and supply chain concerns related to animal- and human-derived materials.

 

Merck’s VirusExpress™ Platform offers a simplified upstream workflow, making processes easier to manage, adjust and scale. Flexible licensing allows companies to manufacture vectors by using either Merck’s contract manufacturing capabilities, a third-party contract development and manufacturing organisation, or in-house development. 

More information online

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment





Digital Edition

Measurement Analysis China 2021 Buyers Guide

November 2020

The following Buyers’ Guide has been produced by International Labmate Ltd. International Labmate have been publishing magazines for over 46 years. We now publish 9 laboratory, environmental and...

View all digital editions

Events

LABComplEX

Oct 27 2020 Kiev, Ukraine

KHIMIA 2020

Oct 27 2020 Moscow, Russia

Thailand Lab 2020 - NEW DATES

Oct 28 2020 Bitec Hall, Bangkok, Thailand

Expomed Eurasia - NEW DATES

Nov 05 2020 Istanbul, Turkey

Pharma Asia - NEW DATES

Nov 10 2020 Karachi, Pakistan

View all events